Clinical trial
Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With…
NCT00473174 · University of Vigo, Other · Completed
Key facts
| NCT number | NCT00473174 |
|---|---|
| Title | Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension |
| Official title | A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential |
| Acronym | HYCCRA |
| Lead sponsor | University of Vigo, Other |
| Collaborators | King Pharmaceuticals is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Device, Drug |
| Interventions | Ramipril, ambulatory blood pressure monitoring |
| Enrollment | 120 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 14, 2007 |
| Last update posted | Sep 2, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: